Study guide
16.3 Reproductive Pathology & Hormone-Related Neoplasia
NBME Comprehensive Basic Science Examination CBSE
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Navigation
1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness
2 Human Development
2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care
3 Blood & Hematologic Disease
3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms
4 Immune System
4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology
5 Nervous System Anatomy & Disease
5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms
6 Behavioral Health
6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science
7 Musculoskeletal System
7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders
8 Skin & Soft Tissue
8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection
9 Cardiovascular Pathophysiology
9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension
10 Cardiovascular Pharmacology
10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs
11 Respiratory System
11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology
12 Renal Physiology & Electrolytes
12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation
13 Renal Pathology
13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease
14 Gastrointestinal System
14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption
15 Endocrine System
15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
16 Reproductive System
16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia
17 Multisystem Processes & Disorders
17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology
18 Biostatistics & Epidemiology
18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health
19 Social Sciences & Communication
19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning
20 Integrated Disciplines Capstone
20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution
16.3 Reproductive Pathology & Hormone-Related Neoplasia
Key Takeaways Explain This Topic AI
PCOS: insulin resistance and disordered gonadotropin drive → ovarian androgen excess, anovulation, unopposed estrogen (endometrial risk), polycystic morphology; treat metabolic drivers and cycle control.
Complete mole is usually 46,XX (paternal only) with diffuse villous swelling, no fetus, very high hCG; partial mole is often 69,XXY with fetal parts. Both are gestational trophoblastic disease; choriocarcinoma is invasive trophoblastic malignancy with high hCG.
Cervical cancer is driven by high-risk HPV E6/E7 (p53 and Rb inactivation); endometrial carcinoma type I is estrogen-related (hyperplasia pathway); ovarian tumors split surface epithelial, germ cell, and sex cord–stromal with marker patterns.
Breast cancer risk rises with cumulative estrogen exposure; receptors ER/PR/HER2 guide therapy. BPH is DHT-sensitive periurethral hyperplasia; prostate cancer is peripheral zone adenocarcinoma with PSA context and osteoblastic mets.
Testicular germ-cell tumors: seminoma (PLAP+, radiosensitive, homogeneous) vs nonseminoma (AFP/hCG patterns, more aggressive). Cryptorchidism raises germ-cell tumor and infertility risk.
Last updated: August 2026
16.3 Reproductive Pathology & Hormone-Related Neoplasia
Quick Answer: PCOS = androgen excess + anovulation + metabolic risk. Endometriosis = ectopic endometrium with cyclic pain/infertility. PID → tubal scarring → ectopic. Complete vs partial mole by karyotype and fetal tissue. HPV E6/E7 → cervical ca. Endometrial ca often estrogen-driven. Know ovarian/breast/prostate/testicular tumor buckets and markers.
This section converts physiology into disease packages. CBSE items often give a lab + morphology hint and ask for the mechanism (e.g., unopposed estrogen, HPV E7–Rb, DHT in BPH, cryptorchid germ-cell risk).
PCOS (Polycystic Ovary Syndrome)
Core pathophysiology (simplified, high-yield):
Insulin resistance → hyperinsulinemia increases ovarian androgen production and lowers SHBG → higher free androgens.
Altered GnRH/LH tone (often elevated LH:FSH ratio in classic teaching) supports theca androgen output.
Androgens impair orderly folliculogenesis → chronic anovulation , oligomenorrhea, cystic follicles on ultrasound ("string of pearls"—supportive, not solely diagnostic).
Anovulation → unopposed estrogen (no cyclic progesterone) → endometrial hyperplasia and endometrial carcinoma risk .
Clinical: hirsutism, acne, obesity/central adiposity common, acanthosis nigricans with insulin resistance, infertility.
Differential anchors: Late-onset CAH (17-OHP), androgen-secreting tumors (rapid virilization, very high testosterone), Cushing, hyperprolactinemia, thyroid disease. Treatment themes: weight loss/exercise; combined OCPs for cycle control and SHBG rise; spironolactone for hirsutism; metformin in insulin resistance/diabetes risk; ovulation induction (letrozole/clomiphene) for fertility—exam focuses more on mechanism than regimens.
Endometriosis
Ectopic endometrial glands and stroma outside the uterus (ovaries → chocolate cysts/endometriomas, pelvic peritoneum, cul-de-sac, uterosacral ligaments). Estrogen-dependent , cyclic hemorrhage → inflammation, fibrosis, adhesions, pain (dysmenorrhea, dyspareunia), and infertility (anatomic + inflammatory).
Theories: retrograde menstruation (Sampson), coelomic metaplasia, lymphatic/vascular spread. Definitive diagnosis historically by laparoscopy; clinically recognized by symptom pattern. OCPs, progestins, GnRH agonists reduce stimulation; surgery for severe disease/fertility—again, mechanism > protocol on CBSE.
PID and Ectopic Pregnancy
Pelvic inflammatory disease usually follows ascending infection ( N. gonorrhoeae , C. trachomatis , polymicrobial anaerobes). Tubal epithelial injury and ciliary damage → salpingitis, tubo-ovarian abscess risk, chronic scarring .
Ectopic pregnancy (most often tubal ampulla): fertilized ovum implants outside endometrium. Risk factors: prior PID/tubal surgery, prior ectopic, assisted reproduction, smoking, IUD in situ (pregnancy rare but if occurs, higher ectopic proportion). Presentation: amenorrhea, unilateral pain, spotting; rupture → acute abdomen and shock. hCG positive with empty uterus on ultrasound and/or inappropriate hCG rise. Pathophysiology link: impaired tubal transport from scarring.
Gestational Trophoblastic Disease
Feature Complete mole Partial mole
Karyotype (classic) 46,XX (usually all paternal; empty ovum + duplicated sperm) or 46,XY paternal 69,XXY (or other triploid) maternal + paternal
- Fetal tissue Absent Present (anomalous)
- Villi Diffuse hydropic swelling; trophoblastic hyperplasia marked Focal hydropic change
- hCG Markedly elevated Moderately elevated
Clinical "Snowstorm" ultrasound, size > dates, hyperemesis, preeclampsia early, theca-lutein cysts Less dramatic
Malignant risk Higher risk of invasive mole / choriocarcinoma Lower than complete
Choriocarcinoma: malignant trophoblast, early hematogenous spread (lung, brain); very high hCG; responds to chemotherapy (methotrexate-based regimens historically classic). Monitor hCG after mole evacuation.
Cervical Cancer and HPV
High-risk HPV (16, 18 most tested) infects transformation zone epithelium. Viral E6 binds p53 → degradation; E7 binds Rb → frees E2F → cell cycle progression. Progression: koilocytes → CIN grades → invasive squamous cell carcinoma (or adenocarcinoma with certain types). Risk cofactors: smoking, immunosuppression, multiple partners, early coitarche, lack of screening.
Screening/prevention concept: Pap/HPV testing catches precursors; vaccination targets major oncogenic (and some low-risk wart) types. Local invasion to parametria/ureters can cause hydronephrosis—classic advanced disease death pathway in older vignettes.
Endometrial Hyperplasia and Carcinoma
Estrogen without adequate opposing progesterone drives endometrial proliferation: obesity (aromatization in fat), anovulation/PCOS, nulliparity, early menarche/late menopause, unopposed estrogen therapy, estrogen-secreting tumors (granulosa cell).
Pathway Features
Type I endometrioid Hyperplasia → atypical hyperplasia → carcinoma; ER-positive; better prognosis; PTEN mutations often cited
Type II (e.g., serous) Atrophic background, p53, older thin women, more aggressive
Protective factors: combined OCPs, multiparity, progesterone exposure. Postmenopausal bleeding is carcinoma until adequately evaluated (exam heuristic).
- Ovarian Tumors (High-Yield Taxonomy)
- Surface epithelial (most common overall in adults)
Serous: cystic, psammoma bodies possible; cystadenoma vs cystadenocarcinoma; most common malignant epithelial type.
Mucinous: multiloculated, mucin; pseudomyxoma risk considerations (appendiceal primary often).
Endometrioid: associated with endometriosis/endometrial carcinoma.
Clear cell / Brenner: less common; Brenner has transitional-like epithelium, coffee-bean nuclei.
Risk: more ovulation (nulliparity), genetic (BRCA, Lynch); protective: OCPs, multiparity, breastfeeding (fewer lifetime ovulations).
Germ cell (younger patients)
- Tumor Marker / pearl
- Dysgerminoma Male seminoma counterpart; LDH , PLAP; radiosensitive
- Yolk sac (endodermal sinus) AFP ; Schiller-Duval bodies
- Choriocarcinoma (ovarian) hCG ; cytotrophoblast + syncytiotrophoblast
- Immature teratoma Malignant germ cell; immature neuroepithelium graded
- Mature cystic teratoma (dermoid) Benign common; teeth/hair; struma ovarii (thyroid) can cause hyperthyroidism
- Sex cord–stromal
Granulosa cell tumor: estrogen secretion → endometrial hyperplasia/bleeding; Call-Exner bodies; inhibin marker.
Sertoli–Leydig: androgens → virilization; rare.
Fibroma: Meigs syndrome (ovarian fibroma + ascites + pleural effusion).
Breast: Fibrocystic Change vs Cancer
Fibrocystic changes: common, hormone-related, cyclic pain/nodularity; blue-dome cysts; apocrine metaplasia; generally benign. Proliferative lesions with atypia raise risk more than nonproliferative fibrocystic change.
Breast carcinoma risk factors: age, female sex, family history/BRCA1/2, dense breasts, early menarche, late menopause, nulliparity, late first pregnancy, combined HRT, radiation, alcohol, obesity (postmenopausal aromatase).
- Receptor profile Therapeutic implication (concept)
- ER/PR positive Hormonal therapy (tamoxifen SERM; aromatase inhibitors in postmenopausal)
- HER2 amplified HER2-targeted therapy (trastuzumab class)
- Triple negative More aggressive; chemo-based strategies; BRCA association
Histology pearls: invasive ductal (most common); lobular (loss of E-cadherin, lines/Indian file); DCIS → microcalcifications on mammography; Paget disease of nipple (DCIS extends to epidermis).
BPH vs Prostate Cancer
- Feature BPH Prostate adenocarcinoma
- Zone Transitional / periurethral Peripheral zone (often posterior—DRE nodule)
- Driver DHT -dependent hyperplasia Multifactorial; androgens permissive
- Symptoms Obstructive/irritative voiding, smooth enlargement May be asymptomatic early; nodule/induration
- PSA Can elevate modestly Elevates; also free/total patterns, velocity—context required
- Mets Does not metastasize Osteoblastic bone mets classic
- Therapy theme α1-blockers, 5α-reductase inhibitors Surgery/radiation/androgen deprivation for advanced
- Testicular Tumors and Cryptorchidism
Cryptorchidism: failure of testicular descent; most resolve spontaneously early, but persistent undescended testes raise infertility (heat-sensitive spermatogenesis) and germ-cell tumor risk—including in the contralateral descended testis to some degree. Orchiopexy facilitates surveillance and may improve fertility potential; tumor risk not fully eliminated.
Germ-cell tumors (≈95% of testicular malignancies)
Type Features / markers
Seminoma Homogeneous, fried-egg cells, PLAP , radiosensitive, better prognosis; hCG occasionally from syncytiotrophoblast elements
- Embryonal carcinoma Aggressive, hemorrhagic/necrotic; may raise AFP/hCG
- Yolk sac Children; AFP ; Schiller-Duval
- Choriocarcinoma hCG very high; hematogenous spread early
Teratoma All three germ layers; mature teratoma in post-pubertal males still considered malignant potential unlike mature ovarian dermoid
Mixed Common; markers follow components
Nonseminomatous GCT often produce AFP and/or hCG ; management and prognosis differ from pure seminoma. Painless mass is the classic presentation; biopsy is not done pre-orchiectomy in standard teaching (spread risk)—orchiectomy is diagnostic/therapeutic.
Sex cord stromal tumors (Leydig cell: Reinke crystals, androgens/estrogens; Sertoli cell) are less common.
Closing Integration Map
Anovulation + unopposed estrogen → PCOS and type I endometrial cancer risk share a pathway.
HPV E6/E7 is the molecular sentence for cervical neoplasia.
Mole karyotype table separates complete vs partial before you guess hCG magnitude.
Zone anatomy separates BPH (transition) from prostate cancer (peripheral).
Markers (hCG, AFP, PLAP, inhibin, ER/PR/HER2) are the fastest way to score tumor questions.
Cryptorchidism links pediatric anatomy to adult oncology and infertility physiology from 16.1.